Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 32, Issue 5, Pages 853-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2018.05.012
Keywords
Waldenstrom macroglobulinemia; BTK; Ibrutinib; Second-generation BTK inhibitors
Categories
Ask authors/readers for more resources
Waldenstrom macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with relapsed/refractory WM. Newer and more selective BTK inhibitors are currently being tested in several clinical trials and are expected to address the toxicity and the acquired resistance observed in patients receiving ibrutinib. Updates on ibrutinib and second-generation BTK inhibitors are summarized in this article.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available